Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

about

Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments.Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

P2860

Q55334029-A8F801D4-2366-4997-AC36-CF72D6FE6D74 Q58770191-079C7269-20D2-4770-B3DF-055FEBF23D2F

P2860

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

Item

http://www.wikidata.org/entity/Q40045541

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effects and safety of oral tol ...... iew and network meta-analysis.

@en

type

Item

label

Effects and safety of oral tol ...... iew and network meta-analysis.

@en

prefLabel

Effects and safety of oral tol ...... iew and network meta-analysis.

@en

P1476

Effects and safety of oral tol ...... iew and network meta-analysis.

@en

P2093

Der-Cherng Tarng

http://www.w3.org/2001/XMLSchema#string

Tzu-Ting Chen

http://www.w3.org/2001/XMLSchema#string

Ying-Chun Chen

http://www.w3.org/2001/XMLSchema#string

Yun-Chun Wu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

P304

e0184380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.1371/JOURNAL.PONE.0184380

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yu-Kang Tu

Hsien-Ho Lin

Mei-Yi Wu

P5008

ScienceSource

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28898297

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

mechanism of action

P932

5595312

http://www.w3.org/2001/XMLSchema#string

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

about

P2860

P2860

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P698

P921

P932